Skip to main content
letter
. 2021 Jul 14;100(3):698–700. doi: 10.1016/j.kint.2021.07.006

Figure 1.

Figure 1

A stronger humoral and cellular immune response in dialysis patients who were convalescent for coronavirus disease 2019 compared with vaccinated dialysis patients. Humoral response was assessed by neutralization assay for the reference strain and for variants of concern alpha and beta strains; and by conventional enzyme-linked immunosorbent assay (ELISA) for the reference strain; T-cell response was evaluated after stimulation with S-protein overlapping peptide pools of corresponding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains and subtracting background activation levels (dimethylsulfoxide). (a) Percentage of patients with a detectable (neutralization) serological response, for Spike (S) protein wild type (WT), alpha, and beta. (b) Neutralization antibody titers for the 3 SARS-CoV-2 strains. The gray area shows donors with a titer below the detection limit. (c) Percentage of patients with a CD4+ T-cell response for reference, alpha, and beta SARS-CoV-2 strains, as defined by a stimulation index >3. (d–f) Percentage of activated CD4+ T cells (d), CD8+ T cells (e), and CD4+CXCR5+ T cells (f) for each of the 3 SARS-CoV-2 strain–derived S-protein overlapping peptide pools. (g) Percentage of effector memory T cells among S-protein–reactive CD4+ T cells.